Prevalence, Clinical Severity, and Serotype Distribution of Pneumococcal Pneumonia Among Adults Hospitalized With Community-Acquired Pneumonia in Tennessee and Georgia, 2018–2022
Clinical Infectious Diseases · 2024
DOI: 10.1093/cid/ciae316 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Infectious Diseases, 2024. Verfasst von Wesley H Self und 20 weiteren Autor:innen. Beteiligte Einrichtung: Vanderbilt Institute for Clinical and Translational Research, Vanderbilt University Medical Center, Nashville, Tennessee, USA. Hauptthemen laut MEDLINE: Community-Acquired Infections, Pneumonia, Pneumococcal, Streptococcus pneumoniae, Serogroup. Die Arbeit wurde bisher 26-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Emory University, NCATS NIH HHS, Merck Sharp & Dohme LLC.
Abstract (Originalsprache)
Introduction
Understanding the pneumococcal serotypes causing community-acquired pneumonia (CAP) is essential for evaluating the impact of pneumococcal vaccines.
Methods
We conducted a prospective surveillance study of adults aged ≥18 years hospitalized with CAP at 3 hospitals in Tennessee and Georgia between 1 September 2018 and 31 October 2022. We assessed for pneumococcal etiology with cultures, the BinaxNOW urinary antigen detection test, and serotype-specific urinary antigen detection assays that detect 30 pneumococcal serotypes contained in the investigational pneumococcal conjugate vaccine V116, as well as licensed vaccines PCV15 and PCV20 (except serotype 15B). The distribution of pneumococcal serotypes was calculated based on serotype-specific urinary antigen detection results.
Results
Among 2917 hospitalized adults enrolled with CAP, 352 (12.1%) patients had Streptococcus pneumoniae detected, including 51 (1.7%) patients with invasive pneumococcal pneumonia. The 8 most commonly detected serotypes were: 3, 22F, 19A, 35B, 9N, 19F, 23A, and 11A. Among 2917 adults with CAP, 272 (9.3%) had a serotype detected that is contained in V116, compared to 196 (6.7%) patients with a serotype contained in PCV20 (P < .001), and 168 (5.8%) patients with a serotype contained in PCV15 (P < .001). A serotype contained in V116 but not PCV15 or PCV20 was detected in 120 (4.1%) patients, representing 38.0% of serotype detections.
Conclusions
Approximately 12% of adults hospitalized with CAP had S. pneumoniae detected, and approximately one-third of the detected pneumococcal serotypes were not contained in PCV15 or PCV20. Development of new pneumococcal vaccines with expanded serotype coverage has the potential to prevent a substantial burden of disease.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Vanderbilt Institute for Clinical and Translational Research, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
- Department of Emergency Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
- Value & Implementation, Outcomes Research, Merck Sharp & Dohme, Rahway, New Jersey, USA.
- Department of Biostatistics, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
- Global Health Institute and Rollins School of Public Health, Emory University, Atlanta, Georgia, USA.
- Department of Medicine, Emory University, Atlanta, Georgia, USA.
ORCID-Profile: Wesley H Self
Förderung
- Emory University
- NCATS NIH HHS
- Merck Sharp & Dohme LLC
- Vanderbilt University Medical Center
- Merck & Co., Inc.
Zitieren
APA
Self, W. H., Johnson, K. D., Resser, J. J., Whitney, C. G., Baughman, A., Kio, M., Grijalva, C. G., Traenkner, J., Johnson, J., Miller, K. F., Rostad, C. A., Yildirim, I., Salazar, L., Tanios, R., Swan, S. A., Zhu, Y., Han, J. H., Weiss, T., Roberts, C., …, & PNEUMO Study Investigators (2024). Prevalence, Clinical Severity, and Serotype Distribution of Pneumococcal Pneumonia Among Adults Hospitalized With Community-Acquired Pneumonia in Tennessee and Georgia, 2018–2022. Clinical Infectious Diseases. https://doi.org/10.1093/cid/ciae316
Vancouver
Self WH, Johnson KD, Resser JJ, Whitney CG, Baughman A, Kio M, et al. Prevalence, Clinical Severity, and Serotype Distribution of Pneumococcal Pneumonia Among Adults Hospitalized With Community-Acquired Pneumonia in Tennessee and Georgia, 2018–2022. Clinical Infectious Diseases. 2024. doi:10.1093/cid/ciae316
BibTeX
@article{Self2024,
author = {Self, Wesley H and Johnson, Kelly D and Resser, J Jackson and Whitney, Cynthia G and Baughman, Adrienne and Kio, Mai and Grijalva, Carlos G and Traenkner, Jessica and Johnson, Jakea and Miller, Karen F and Rostad, Christina A and Yildirim, Inci and Salazar, Luis and Tanios, Ralph and Swan, Sydney A and Zhu, Yuwei and Han, Jin H and Weiss, Thomas and Roberts, Craig and Rouphael, Nadine and PNEUMO Study Investigators, PNEUMO Study Investigators},
title = {Prevalence, Clinical Severity, and Serotype Distribution of Pneumococcal Pneumonia Among Adults Hospitalized With Community-Acquired Pneumonia in Tennessee and Georgia, 2018–2022},
journal = {Clinical Infectious Diseases},
year = {2024},
doi = {10.1093/cid/ciae316}
}
EUVIMED